Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • New light based...

    New light based Illuvinate System now available for Plaque Psoriasis

    Written by Vinay Singh singh Published On 2018-12-09T19:10:09+05:30  |  Updated On 9 Dec 2018 7:10 PM IST
    New light based Illuvinate System now available for Plaque Psoriasis

    The U.S FDA has approved, illuvinate system, a light-based therapy to treat plaque psoriasis, announced Luma Therapeutics. The system is intended for at-home use.


    The device delivers ultraviolet light, within a narrow spectrum, to the skin using a powerful-stick on LED array, as well as humidification to soothe the area. Illuvinate can now be prescribed either by a dermatologist or via Luma’s telehealth provider.


    The treatment is based on Goeckerman therapy. It is a regimen which dates back to the 1920s and involves applying coal tar to a patient's skin and exposing the skin to ultraviolet light. With the increased use of biologic medications in the treatment of moderate-to-severe psoriasis, there has been a shift away from Goeckerman therapy.


    Read Also: New drug launched for moderate-to-severe plaque psoriasis


    Illuvinate has been demonstrated to reduce local inflammation, rehydrate the skin and restore normal skin cells. The system includes patented hydrating technology with coal tar, a narrowband UV LED light system and a proprietary app-based dosing algorithm. The therapy is applied for just minutes each day over a six-week period from the comfort and convenience of home.


    Current common treatments for psoriasis fall short: topical steroid treatments can be messy and ineffective, and many patients are reluctant to take medications that may have long-term side effects. Other treatments are only available in a clinical setting, presenting an obstacle to consistent adherence


    "Many [psoriasis] patients are hesitant to consistently use medications, which may have long-term side effects," said Jeffrey Sugarman, MD, Ph.D., Luma's CMO. "As a result, patients become discouraged and stop seeking treatment from a dermatologist. I believe that the illuvinate System will be a great option for many patients."


    Read Also: Promising new treatment option for chronic plaque psoriasis


    Plaque psoriasis is an inherited systemic inflammatory disease of immune dysfunction that causes plaques of elevated, scaling, inflamed skin that is often quite itchy. The plaques are characteristically found on the scalp, elbows, and knees. Plaque psoriasis is relatively common; about 2%-3% of the population of the United States is affected. It is not contagious.


    biologiccoaldermatologistFDAFood and Drug AdministrationGoeckermanhydratingilluvinateJeffrey SugarmanLEDlightMedicinesmoderateplaquepsoriasissevereskinsystemtartherapytreatmentultravioletUSUV

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok